Turning Point is a precision oncology company with a focus on creating investigational drugs to improve cancer therapies. The company's lead drug candidate, repotrectinib, is a kinase inhibitor that targets non-small cell lung cancer and tumors. The drug is currently being studied in clinical trials and has shown promising results. The company also has a pipeline of other drug candidates, including TPX-0022, TPX-0046, and TPX-0131, which are all in various phases of clinical development.